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Abstract. The presence of androgen receptors (AR) in 
neuroendocrine c lls was investigated in benign tissue of 
10 prostatectomy specimens, in 12 prostatic adenocar- 
cinomas with focal neuroendocrine differentiation a d in 
1 case of a pure neuroendocrine small cell carcinoma of 
the prostate. Neuroendocrine c lls were defined by their 
reactivity with an antibody to chromogranin A. Mono- 
clonal antibody F39.4 directed against he amino-termi- 
nal domain of the AR molecule was used to detect AR. 
AR and chromogranin A were simultaneously visualized 
with a double immunofluorescence technique. The re- 
sults indicate that chromogranin positive cells in both 
benign and malignant prostatic tissue lack detectable ex- 
pression of AR. No effect of endocrine therapy was noted. 
These results are in agreement with the hypothesis that 
prostatic neuroendocrine tumour cells represent an an- 
drogen insensitive cell population, which incidentally 
may expand to replace the androgen-sensitive tumour 
cell population during androgen ablation therapy. 
Introduction 
Most patients with metastasized prostate cancer benefit 
initially from androgen ablation therapy, but about 20 % 
of cases are refractory to endocrine therapy (Lepor et al. 
1982; Paulson 1983). The high response rate is in accor- 
dance with the observation that most human prostate 
cancers have a high content of androgen receptors (AR; 
Martelli et al. 1980; Concolino et al. 1982). Some recent 
immunohistochemical studies using antibodies to the 
amino-terminal domain of AR revealed that the propor- 
tion of AR positive tumour cells varied among prostate 
cancers; poorly differentiated prostate c ncers tended to 
have a diminished proportion of AR positive tumour 
cells (Ruizeveld e Winter et al. 1990; Masai et al. 1990). 
In ligand binding studies on tumour cytosols, Gorelic et 
al. (1987) similarly noted heterogeneity of AR expression 
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in prostate cancer. It can be envisaged that androgen 
withdrawal would lead to the selective xpansion of the 
subset of AR negative tumour cells; however, in a 
previous paper we reported that the majority of hormone 
therapy-resistant prostate cancers consists largely of AR 
positive tumour cells (Van der Kwast et al. 1991). The 
mechanism underlying the transition to hormone in- 
dependence still remains unclear. 
Neuroendocrine c lls producing a variety of peptide 
hormones are dispersed in the epithelial lining ofprostat- 
ic ducts and glands. Peptide hormones are thought o 
play a regulatory role during the growth and iffer- 
entiation of the prostate (reviewed by Di Sant'Agnese 
1992). Similarly, neuroendocrine c lls may be found in 
human prostate cancer, generally as a minor component, 
but occasionally constituting the entire neoplastic ell 
population. A few retrospective studies on prostate can- 
cer have indicated that an increase in the proportion of 
tumour cells with neuroendocrine differentiation is nega- 
tively correlated with prognosis (Turbat-Herrera et al. 
1988; Cohen et al. 1990). Abrahamsson et al. (1989) 
demonstrated an enrichment for tumour cells with neuro- 
endocrine differentiation after oestrogen therapy of pros- 
tate cancer. Furthermore, some cases of prostate cancer 
with a minor neuroendocrine population showed a tran- 
sition to a pure neuroendocrine malignancy after estab- 
lishment of endocrine therapy (Stratton et al. 1986; T~tu 
et al. 1987). The latter observations suggest that prostatic 
tumour cells with neuroendocrine differentiation are not 
androgen sensitive and may be involved in the develop- 
ment of androgen unresponsiveness. The present study 
was undertaken to examine whether or not neuro- 
endocrine cells in benign prostatic tissue and in prostate 
cancer are lacking in androgen receptors. 
Materials and methods 
Tissue specimens 
Tissue specimens were obtained from patients with an established 
diagnosis of prostatic carcinoma and who underwent prostatec- 
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Table i. Presence of chromogranin A pos- 
itive cells in prostatic arcinomas Surgery a Grading b Endocrine Duration Number of 
therapy (months) cells °
TUR 1 (3) None 4 
TUR 1 (3) None 42 
Radical 1 (3) None 35 
TUR 2 (4) CPA 20 36 
Radical 2 (4) None 57 
TUR 3 (4) None 60 
TUR 3 (4) CPA 98 46 
TUR 3 (5) None 20 
TUR 3 (5) None 35 
TUR 3 (5) Orchidect 20 3 
TUR 3 (5) Goserelin 4 4 
TUR 3 (5) Orchidect 12 7 
TUR 3 (5) Orchidect 48 65 
TUR Small cell None 
TUR, Transurethral resection; CPA, cyproterone acetate 
a Surgery consisted of TUR or radical prostatectomy 
b Prostatic arcinomas were scored according to the M.D. Anderson grading system; the 
Gleason growth pattern is given in parentheses 
° The number of chromogranin A positive turnout cells examined for androgen receptor 
expression is given 
tomy (n= 10) or transurethral resection (n= 12). These cases had 
been selected from a larger series of prostatic arcinomas on the 
basis of the presence of neuroendocrine cells. The clinical data and 
the classification of the examined tumours according to the grading 
system of M.D. Anderson and the Gleason growth pattern (Ten 
Kate et al. 1986) are presented in Table 1. In six cases the tumour 
showed progressive growth despite androgen ablation therapy. The 
prostatic genesis of the small cell (neuroendocrine) carcinoma was 
endorsed by the absence of a pulmonary tumour in the patient. 
Benign prostatic tissue was derived from parts of prostatectomy 
specimens that were not involved in the neoplastic process. Im- 
mediately after surgery the tissue samples were frozen in chilled 
isopentane and stored in liquid nitrogen until use. 
Immunohistochemistry and immunofluorescence 
Immunohistochemistry and immunofluorescence were performed 
on cryostat sections of 4 gm in thickness. Expression of chromogra- 
nin A was visualized with a monoclonal ntibody obtained commer- 
cially from Organon Technika, The Netherlands; the antibody was 
diluted 1 : 80 in phosphate-buffered saline (PBS) before using in the 
assay. Binding of the anti-chromogranin antibody was visualized by 
the indirect conjugated peroxidase method. Frozen sections were 
fixed for l0 min in 4% formalin in PBS prior to incubation with 
anti-chromogranin, as this fixation enhances the sensitivity of detec- 
tion in comparison to acetone-fixed frozen sections. For detection 
of AR, monoclonal antibody F39.4 raised against amino acids 
300-320 of the human AR molecule was applied (Zegers et al. 1991). 
Preliminary experiments indicated that a sequential double 
immunoenzymatic method for simultaneous detection of AR and 
chromogranin did not yield satisfactory results: the im- 
munoperoxidase taining for AR interfered with the subsequent 
demonstration of chromogranin. Therefore a double-immu- 
noftuorescence method was developed for use on cryostat sections, 
according to the following procedure. The sections were fixed in 4% 
formalin in PBS, rinsed in PBS for 5 rain, and dehydrated inchilled 
( -20  ° C) methanol for 4 min and chilled acetone for 2 min. The 
slides were subsequently rinsed in PBS and preincubated with non- 
immune goat serum (DAKO, Glostrup, Denmark) for 15 min. 
After an overnight incubation with F39.4 diluted 1:4000, the slides 
were incubated sequentially for 30min each with biotinylated goat 
anti-mouse immunoglobulin (Ig; DAKO) diluted 1:400 in PBS, 
avidin-conjugated fluorescein isothiocyanate (FITC) diluted 1 : 200 
in PBS, biotinylated goat anti-avidin diluted 1 : 200, and again with 
avidin-FITC. Between incubations the slides were rinsed in PBS. 
To demonstrate chromogranin A by double immunoftuores- 
cence, the slides were subsequently exposed to anti-chromogranin 
A (diluted 1:80), alkaline phosphatase labelled rabbit anti-mouse 
Ig and the substrate naphthol ASB and Fast Red obtained from the 
Vector substrate kit (Vector, Burlingame, Calif., USA). The sub- 
strate was dissolved in 4 % polyvinyl alcohol mol. wt. 49 000 (Fluka, 
Neu-Ulm, Germany) in order to reduce the diffusion of the pre- 
cipitate. After rinsing in distilled water the slides were covered with 
Vectashield (Vector) and a coverslip. Evaluation was performed 
with a Zeiss light microscope quipped with an excitation filter of 
450-500 nm and an LP515 long-pass filter. A KP560 interference 
red-free filter was used to detect AR selectively. 
Control slides were incubated with all the reagents mentioned 
above, but either F39.4 or anti-chromogranin A or both antibodies 
were replaced by PBS. No non-specific background fuorescence for 
nuclei and cytoplasm respectively or both was noted in these slides. 
As a control for the feasibility of using double immunofluorescence 
to detect acytoplasmic marker and nuclear AR within the same cell, 
the anti-chromogranin a tibody was replaced by mouse mono- 
clonal antibody ER-PR1, specific for prostate specific antigen 
(PSA; Gallee et al. 1986). The double-immunofluorescence tech- 
nique clearly demonstrated the simultaneous expression of nuclear 
AR and cytoplasmic PSA in the secretory epithelial cells lining 
prostatic glands (Fig. 1). 
Results 
Benign prostatic tissue 
Neuroendocr ine  cells demonst ra ted  by their reactivity 
with ant i - chromogran in  A ant ibody  were observed 
predominant ly  a long prostat ic  ducts, but  also in the 
l in ing of  prostat ic  glands. Most  f requent ly  they occurred 
as single cells, but  occasional ly  in small  clusters. The 
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neuroendocrine c lls were located in a basal position. In 
double-immunofluorescence staining, the nuclei of the 
luminal, but not basal epithelial cells, were distinctly 
labelled. In none of a total of 100 chromogranin-positive 
cells examined in the benign prostatic glands of 10 differ- 
ent prostatectomy specimens was AR expression detect- 
able (Figs. 2 and 3). 
Prostatic cancer 
Immunohistochemistry for chromogranin was per- 
formed on a series of 12 transurethrally resected tissue 
specimens and on two prostatectomy derived tissue sam- 
ples. Thirteen prostatic carcinomas contained variable 
numbers of tumour cells with neuroendocrine differ- 
entiation. In some tumours the neuroendocrine c lls were 
present in small foci. Double-immunofluorescence stud- 
ies of these tissue samples failed to demonstrate the 
presence of AR in chromogranin A-positive cells (Figs. 4 
and 5), although the nuclei of the surrounding chromo- 
granin A-negative cells were intensely labelled for AR. 
No effect of endocrine therapy was observed on the 
expression of AR in neuroendocrine and non-neuro- 
endocrine cells (Table 1). One transurethrally resected 
specimen contained a small cell carcinoma, which was 
largely composed of chromogranin-positive tumour cells. 
With F39.4 antibody only sporadic faintly AR positive 
tumour cells were seen in this tumour (Fig. 6). 
Discussion 
This study has demonstrated that prostatic neuroendo- 
crine cells lack a detectable expression of AR. This ob- 
servation holds true for neuroendocrine c lls lining be- 
nign prostatic glands and ducts, and also for those which 
are an intrinsic component of prostatic adenocar- 
cinomas. The differentiation grade of the prostatic ar- 
cinoma did not affect the outcome of the results (Ta- 
ble 1). In addition, we showed that the pure neuroendo- 
crine small cell prostatic carcinoma lacked detectable 
AR. The latter is in accordance with the reported absence 
of AR in a xenografted small cell neuroendocrine car- 
cinoma line originating from a human prostatic car- 
cinoma (Van Haaften-Day et al. 1987). 
The more aggressive biological behaviour of prostatic 
carcinomas with a neuroendocrine component has been 
attributed to a lack of responsiveness of the neuroendo- 
crine cells to androgen ablation therapy (Di Sant'Agnese 
1992). This results in an enrichment for the neuroendo- 
crine tumour component. The AR negative, androgen 
insensitive neuroendocrine tumour cells, if endowed with 
the capacity to proliferate, could eventually give rise to 
the development of a pure neuroendocrine carcinoma 
(Stratton et al. 1986; T~tu et al. 1987). The lack of 
detectable AR observed in neuroendocrine prostatic (tu- 
mour) cells is in complete agreement with the above 
hypothesis. However in a recent study, Nakada et al. 
(1993) failed to demonstrate a difference in AR ex- 
pression between on-neuroendocrine and neuroendo- 
crine cells in benign and malignant prostatic tissues. 
These authors used antibody ANI-15 for detection of 
AR. The reactivity of this antibody with the nuclei of 
basal cells lining the prostatic glands, as reported by 
Masai et al. (1990), contrasts with the reactivity pattern 
of antibody F39.4 (Ruizeveld e Winter et al. 1991). In 
addition, differences in tissue processing and in the dou- 
ble-immunostaining technique may help to explain the 
discrepancy of the findings reported by these authors. 
It should be noted that the (therapy-induced) tran- 
sition of a prostatic adenocarcinoma into a frankly new 
roendocrine carcinoma is a very infrequent phenomenon. 
Moreover, about 80% of endocrine therapy-resistant 
progressive prostatic arcinomas contain a high propor- 
tion of AR positive tumour cells (Van der Kwast et al. 
1991). This implies that the presence of AR within pros- 
tatic carcinoma cells does not necessarily indicate their 
androgen dependence. 
Dispersed neuroendocrine tumour cells might in- 
fluence the proliferation of surrounding non-neuroendo- 
crine prostatic tumour cells by paracrine stimulation. A
variety of peptide hormones have been demonstrated in 
prostatic neuroendocrine cells by immunohistochemis- 
try. Several of these peptides are known to have growth 
factor-like activity and may play a paracrine role in the 
development of hormone independence of AR positive 
prostatic adenocarcinoma cells (Di Sant'Agnese 1992). 
In this paper we have shown that in prostatic adenocar- 
cinomas with focal neuroendocrine differentiation, most 
of the surrounding non-neuroendocrine tumour cells dis- 
play nuclear AR expression, independently of the 
previous therapeutic regimen. Power et al. (1991) demon- 
strated that a catecholamine eurotransmitter could in- 
duce ligand-independent activation of some steroid re- 
ceptors (progesterone receptor and oestrogen receptor) 
via a cell membrane associated opamine receptor. If a 
similar ligand independent activation mechanism also 
applies to AR, biogenic amines derived from neuroendo- 
crine cells could similarly play a major role in the process 
of androgen independent activation of (AR positive) 
tumour ceils. 
Although the secretory epithelial cells of prostatic 
glands are AR positive, the basal cells generally resemble 
neuroendocrine c lls in that they lack a detectable AR 
(Ruizeveld e Winter et al. 1991). This common feature 
suggests a close relationship between the two cell types. 
Some authors have speculated on the multidirectional 
differentiation of a prostatic stem cell into either secreto- 
ry epithelial cells or neuroendocrine c lls (Schron et al. 
1984; DeLellis et al. 1984; Roy et al. 1987). Further ex- 
perimental studies should be designed with the aim of 
identifying and characterizing the factors involved in the 
induction of neuroendocrine differentiation i prostatic 
epithelium. 
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Fig. 1. Photomicrograph of benign 
prostatic gland demonstrating an- 
drogen receptor (AR; green) and 
prostate specific antigen (PSA; red) 
in secretory epithelial cells. Left 
panel, Simultaneous demonstration 
of AR and PSA; right panel, in- 
tense nuclear fluorescence for AR 
( x 40) 
Fig. 3. Higher magnification of
neuroendocrine c ll surrounded by 
secretory epithelial cells in benign 
gland. Left panel, Simultaneous 
demonstration f AR and chromo- 
granin A; right panel, intense nu- 
clear fluorescence for AR. Note 
that the neuroendocrine c ll does 
not display nuclear fluorescence for 
AR ( x 250) 
Fig. 5. Photomicrograph of glan- 
dular formations in a moderately 
differentiated adenocarcinoma with 
some neuroendocrine tumour cells. 
Left panel, Simultaneous 
demonstration f AR and chromo- 
granin A; chromogranin positive 
cells are surrounded by AR positive 
tumour cells. Riyht panel, intense 
nuclear fluorescence for AR. Note 
that the neuroendocrine c lls do not 
display nuclear fluorescence for AR 
( x 100) 
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Fig. 2. Low power photomicro- 
graph of benign prostatic gland de- 
monstrating AR (green) and 
chromogranin A (red). Left panel, 
Simultaneous demonstration of AR 
and chromogranin A; right panel, 
intense nuclear fluorescence for AR. 
Note that the neuroendocrine c lls 
do not display AR ( x 40) 
Fig. 4. Focal area with neuroendo- 
crine differentiation i poorly differ- 
entiated adenocarcinoma. AR nega- 
tive neuroendocrine c lls are sur- 
rounded by AR positive non-neuro- 
endocrine tumour cells (x  100) 
Fig. 6. Immunostaining of a pros- 
tatic small cell carcinoma with anti- 
AR antibody (left) and anti- 
chromogranin A (right). The tu- 
mour is largely AR negative, while 
AR positive tumour cells are rarely 
encountered (left). Most tumour 
cells express chromogranin A 
(right) (x  100) 
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